Evidence map›Paper›PMID 36183175›Full record

ArticleTropical medicine & international health : TM & IH2022

Impact of prophylactic antimalarials in pregnant women living with Human Immunodeficiency Virus on birth outcomes in Botswana.

Omonike Arike Olaleye, Rebecca Zash, Modiegi Diseko, Gloria Mayondi, Judith Mabuta, Shahin Lockman, M Lendsey Melton, Mompati Mmalane, Joseph Makhema, Roger L Shapiro

Open access · hybridAbstract read
In one paragraph

Article in Tropical medicine & international health : TM & IH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Omonike Arike OlaleyeCollege of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA.
Rebecca ZashDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Modiegi DisekoBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Gloria MayondiBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Judith MabutaBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
M Lendsey MeltonDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Mompati MmalaneBotswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
Joseph MakhemaDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Roger L ShapiroDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Botswana Harvard AIDS Institute Partnership · BWHarvard University · USTexas Southern University · US

Funding

Targeted Nano-drug-delivery-systems of Frist-in-class Drugs for CRPC: PK/PD Evaluation and Combination TherapyU54MD007605 · NIMHD · TEXAS SOUTHERN UNIVERSITY · PI Dong Liang, Huan Xie · 2020 to 2026
$22.0M
Botswana Birth Outcomes Surveillance ExtensionR01HD095766 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2018 to 2022
$3.3M
Birth Outcomes Surveillance in BotswanaR01HD080471 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, ROGER L · 2014 to 2018
$2.6M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
NIAID NIH HHS K24 AI131924NICHD NIH HHS R01 HD080471NICHD NIH HHS R01 HD095766NIH HHS 5U54MD007605-28NIH HHS R01 HD080471NIMHD NIH HHS U54 MD007605
6 · The paper itself

Abstract

objectivesUntil late 2015, Botswana recommended preventive treatment for pregnant women in malarial regions with chloroquine and proguanil (CP). The guideline change provided an opportunity to evaluate CP and adverse birth outcomes.

methodsThe Tsepamo Study performed birth outcomes surveillance at large delivery centres throughout Botswana. We evaluated adverse birth outcomes from 2015 to 2017 at three hospitals where 93% of CP use was recorded. Outcomes included neonatal death (NND), small for gestational age (SGA), very SGA, stillbirth (SB), preterm delivery (PTD) and very PTD. Logistic regression analysis (unadjusted and adjusted) was conducted for each adverse birth outcome.

resultsDuring the study period, 5883 (26%) of 23,033 deliveries were exposed to CP, with the majority (65%) in the most malaria-endemic region. At this site, there was a trend or an association between CP use and reduction of three adverse birth outcomes: PTD (aOR 0.85, 95% CI 0.76-0.96), vPTD (aOR 0.83, 95% CI 0.68-1.01) and NND (aOR 0.65, 95% CI 0.42-1.00). However, at the least malaria-endemic site, the association was in the opposite direction for SB (aOR 1.54, 95% CI 1.08-2.22), SGA (aOR 1.24, 95% CI 1.06-1.44) and vSGA (aOR 1.42, 95% CI 1.14-1.77). The association between CP and reduced PTD was present among women without HIV (aOR 0.77, 95% CI 0.67-0.89) but not among women with HIV (aOR 1.09, 95% CI 0.78-1.35).

conclusionsAntimalarial prophylaxis was associated with improved birth outcomes in the most malaria-endemic region of Botswana, but not elsewhere. This finding supports current WHO guidance to use prophylaxis strategies among pregnant women in highly malaria-endemic regions. Further studies of the risks and benefits of specific antimalarial regimens in pregnancy are warranted, particularly in areas with lower incidence of malaria.

Indexed as

AntimalarialsHIV InfectionsMalariaPregnancy Complications, InfectiousPremature BirthBotswanaChloroquineFemaleHIVHumansInfant, NewbornPregnancyPregnancy OutcomePregnant PeopleStillbirthAntimalarialsChloroquineantimalarial prophylaxisbirth outcomesBotswanaHIVpregnancy

Identifiers

PMID36183175
PMCPMC9855025
OpenAlexW4298858014

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.